

## **Certificate of Analysis for NR-403**

## Campylobacter jejuni, Strain INP21

Catalog No. NR-403

(Derived from ATCC® BAA-530™)

**Product Description:** Campylobacter jejuni (C. jejuni), strain INP21 was originally isolated by Irving Nachamkin and Patricia Arzarte in 1997 from a patient with Guillain-Barré syndrome at the National Institute of Pediatrics in Mexico City, Mexico.

Lot<sup>1</sup>: 7642596 Manufacturing Date: 16NOV2006

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis <sup>2</sup>		
Cellular morphology	Gram-negative rod	Gram-negative rod
Colony morphology <sup>3</sup>	Report results	Circular, low convex, glistening
Biochemical tests		
Oxidase	Positive	Positive
Catalase	Positive	Positive
Urease	Negative	Negative
Nitrate reduction	Positive	Positive
H <sub>2</sub> S production	Negative	Negative
Hippurate hydrolysis	Positive	Positive
Antibiotic susceptibility		
Nalidixic acid	Sensitive <sup>4</sup>	Sensitive
Cephalothin	Resistant	Resistant
Viability (25°C, 5 days)	No growth	No growth
Viability (42°C, 5 days)	Growth	Growth
FAME	Consistent with Campylobacter jejuni	Consistent with Campylobacter jejuni
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1190 base pairs)	Consistent with Campylobacter jejuni	Consistent with Campylobacter jejun <sup>5</sup>
Viability (post-vialing) <sup>3</sup>	Growth	Growth

<sup>&</sup>lt;sup>1</sup>NR-403 was produced by inoculation of ATCC<sup>®</sup> BAA-530™ (Lot 2722121) into Brucella broth on Tryptic Soy agar with 5% defibrinated sheep blood kolles and incubated for 1 day at 37°C in a microaerophilic (3–5% O₂ and 5% CO₂) atmosphere.

Date: 22 MAR 2017 Signature:

**BEI Resources Authentication** 

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

**BEI Resources** 

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>Hunt, J. M., C. Abeyta, and T. Tran. <u>Bacteriological Analytical Manual</u>, 8th Edition, Revision A. U.S. Food and Drug Administration 1998. 26-04-2007 <a href="http://www.cfsan.fda.gov/~ebam/bam-7.html">http://www.cfsan.fda.gov/~ebam/bam-7.html</a>.

<sup>&</sup>lt;sup>3</sup>2 days at 37°C in a microaerophilic (3–5% O<sub>2</sub> and 5% CO<sub>2</sub>) atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood.

<sup>&</sup>lt;sup>4</sup>Nalidixic acid-resistant *C. jejuni* have been reported.

<sup>&</sup>lt;sup>5</sup>Also consistent with *Campylobacter coli*.